Alpha Cognition Inc. (NASDAQ: ACOG) will present at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025, at the Marriott Marquis Hotel in New York City. The commercial-stage biopharmaceutical company focuses on developing treatments for neurodegenerative diseases including Alzheimer's Disease and Cognitive Impairment with mild Traumatic Brain Injury, conditions that currently lack approved treatment options. Michael McFadden, CEO of Alpha Cognition, expressed enthusiasm about the opportunity to share the company's progress with investors.
The Spartan Capital Conference serves as a strategic platform for Alpha Cognition to highlight commercial and pipeline advancements while building relationships within the capital markets community. This participation reflects the conference's broader mission to connect innovative growth companies with serious capital providers. John D. Lowry, Founder and CEO of Spartan Capital Securities, emphasized the firm's commitment to helping growth companies access appropriate investors and resources. The conference represents an extension of Spartan Capital's reputation for bringing together high-quality issuers and institutional investors.
Organized in partnership with B2i Digital, the event will feature more than 60 carefully selected companies across multiple high-growth sectors, with over 500 institutional and high-net-worth investors expected to attend. David Shapiro, CEO of B2i Digital, noted that Alpha Cognition's invitation resulted from collaboration with Spartan Capital's banking team. Their participation aligns with B2i Digital's mission to combine digital marketing reach with face-to-face investor engagement. The conference will include main-stage presentations, expert panels, curated one-on-one meetings, and networking sessions designed to facilitate meaningful dialogue between growth companies and the investment community. For more information about the conference and registration details, please visit https://spartancapital.com.
The event's structure provides Alpha Cognition with multiple avenues to communicate its value proposition to potential investors. As a company operating in the challenging neurodegenerative disease space, where treatment options remain limited, access to capital markets through events like this conference could significantly impact the company's ability to advance its research and development efforts. The conference's focus on connecting innovative companies with institutional investors comes at a time when biopharmaceutical companies require substantial funding to navigate clinical trials and regulatory pathways.
